[{"id":"d7a0703a-8b1b-461b-a082-3de4e2b533f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03061188","created_at":"2021-01-17T18:03:06.477Z","updated_at":"2025-02-25T14:37:19.874Z","phase":"Phase 1","brief_title":"Phase I/Ib Study of Nivolumab \u0026 Veliparib in Patients With Advanced Solid Tumors \u0026 Lymphoma","source_id_and_acronym":"NCT03061188","lead_sponsor":"Northwestern University","biomarkers":" BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC","pipe":" | ","alterations":" MSI-H/dMMR • RAD50 mutation","tags":["BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAD50 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 05/23/2017","start_date":" 05/23/2017","primary_txt":" Primary completion: 03/11/2018","primary_completion_date":" 03/11/2018","study_txt":" Completion: 08/04/2020","study_completion_date":" 08/04/2020","last_update_posted":"2024-06-12"},{"id":"40c5a9dd-b0cf-48c4-bf22-51d4452040b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03448718","created_at":"2021-01-18T17:00:17.468Z","updated_at":"2025-02-25T14:58:45.009Z","phase":"Phase 2","brief_title":"Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations","source_id_and_acronym":"NCT03448718","lead_sponsor":"Matthew Galsky","biomarkers":" BRCA1 • BRCA2 • ATM • POLE • ERCC2 • ATRX • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • NBN • RAD54L • ERCC5 • FANCF • WRN • XRCC2 • ERCC4 • RAD52 • ERCC3 • FANCD2 • FANCE • FANCG • RECQL4 • FANCB • FANCC • XRCC3","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • POLE • ERCC2 • ATRX • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • NBN • RAD54L • ERCC5 • FANCF • WRN • XRCC2 • ERCC4 • RAD52 • ERCC3 • FANCD2 • FANCE • FANCG • RECQL4 • FANCB • FANCC • XRCC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/17/2018","start_date":" 04/17/2018","primary_txt":" Primary completion: 07/14/2021","primary_completion_date":" 07/14/2021","study_txt":" Completion: 10/15/2021","study_completion_date":" 10/15/2021","last_update_posted":"2023-11-22"},{"id":"419a98b5-d2bf-415b-9307-4fc2b382b434","acronym":"TOMAS","url":"https://clinicaltrials.gov/study/NCT02398058","created_at":"2021-04-14T18:53:45.928Z","updated_at":"2025-02-25T15:06:31.322Z","phase":"Phase 1","brief_title":"Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)","source_id_and_acronym":"NCT02398058 - TOMAS","lead_sponsor":"Italian Sarcoma Group","biomarkers":" BRCA1 • ERCC1 • ERCC2 • PARP1 • TP53BP1","pipe":"","alterations":" ","tags":["BRCA1 • ERCC1 • ERCC2 • PARP1 • TP53BP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Yondelis (trabectedin)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/20/2014","start_date":" 07/20/2014","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2021-04-14"},{"id":"3104391b-e3f1-42cd-bf6a-12a8612992d6","acronym":"CUARTET","url":"https://clinicaltrials.gov/study/NCT04601441","created_at":"2021-01-19T20:30:33.227Z","updated_at":"2024-07-02T16:36:37.659Z","phase":"Phase 4","brief_title":"Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan","source_id_and_acronym":"NCT04601441 - CUARTET","lead_sponsor":"Kindai University","biomarkers":" KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1","pipe":"","alterations":" ","tags":["KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2020-12-08"},{"id":"01034882-ff09-4402-95a9-db47dc9eb1f2","acronym":"OPHELIA","url":"https://clinicaltrials.gov/study/NCT02882308","created_at":"2021-01-18T14:08:53.097Z","updated_at":"2025-02-25T15:07:14.796Z","phase":"Phase 2","brief_title":"Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.","source_id_and_acronym":"NCT02882308 - OPHELIA","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" PD-L1 • BRCA1 • BRCA2 • ERCC1 • ERCC2 • RAD51C • GSTP1 • PARP1 • XRCC1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • BRCA1 • BRCA2 • ERCC1 • ERCC2 • RAD51C • GSTP1 • PARP1 • XRCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin • Imfinzi (durvalumab)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 10/20/2016","start_date":" 10/20/2016","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 01/10/2020","study_completion_date":" 01/10/2020","last_update_posted":"2020-02-07"},{"id":"b6337e86-0dc4-4ad8-a712-c5f23b88b4b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00728000","created_at":"2021-01-19T08:28:53.247Z","updated_at":"2024-07-02T16:36:53.242Z","phase":"Phase 2","brief_title":"Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT00728000","lead_sponsor":"University of Cincinnati","biomarkers":" ERCC1 • ERCC2 • DCK","pipe":"","alterations":" ","tags":["ERCC1 • ERCC2 • DCK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gemcitabine • oxaliplatin"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2008","start_date":" 08/01/2008","primary_txt":" Primary completion: 08/01/2009","primary_completion_date":" 08/01/2009","study_txt":" Completion: 08/01/2010","study_completion_date":" 08/01/2010","last_update_posted":"2019-11-25"},{"id":"65218a54-e210-4ab0-8e4e-95815cb207e1","acronym":"FOXAGAST","url":"https://clinicaltrials.gov/study/NCT02486601","created_at":"2021-01-18T11:58:56.400Z","updated_at":"2025-02-25T14:35:41.494Z","phase":"Phase 2","brief_title":"NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma","source_id_and_acronym":"NCT02486601 - FOXAGAST","lead_sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","biomarkers":" HER-2 • ERCC2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ERCC2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium"],"overall_status":"Unknown status","enrollment":" Enrollment 55","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2019-02-27"},{"id":"a5153a1b-85a7-44cc-b3c7-2bede2580d41","acronym":"","url":"https://clinicaltrials.gov/study/NCT00711243","created_at":"2021-01-18T02:39:41.351Z","updated_at":"2024-07-02T16:37:02.424Z","phase":"Phase 1/2","brief_title":"Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor","source_id_and_acronym":"NCT00711243","lead_sponsor":"Northwestern University","biomarkers":" ERCC2 • CYP3A4 • CYP3A5 • XRCC1","pipe":"","alterations":" ","tags":["ERCC2 • CYP3A4 • CYP3A5 • XRCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • 5-fluorouracil • oxaliplatin"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 04/20/2005","start_date":" 04/20/2005","primary_txt":" Primary completion: 12/15/2008","primary_completion_date":" 12/15/2008","study_txt":" Completion: 02/25/2011","study_completion_date":" 02/25/2011","last_update_posted":"2019-02-26"}]